Epigenetic modulation in cancer immunotherapy

Stuart J. Gallagher, Elena Shklovskaya, Peter Hersey

Research output: Contribution to journalReview articlepeer-review

33 Citations (Scopus)

Abstract

The success of immune checkpoint inhibitors in cancer immunotherapy has been widely heralded. However many cancer patients do not respond to immune checkpoint therapy and some relapse due to acquired tumor resistance. Epigenetic targeting may be beneficial in cancer immunotherapy by reversing immune avoidance and escape mechanisms employed by cancer cells, as well as by modulating immune cell differentiation and function. In this manuscript we review recent findings suggesting how epigenetics may be used to improve cancer immunotherapy. We focus on the inhibitors of the CTLA4 and PD1 immune checkpoints and epigenetic modifiers of histone acetylation and methylation and DNA methylation.

Original languageEnglish
Pages (from-to)48-56
Number of pages9
JournalCurrent Opinion in Pharmacology
Volume35
DOIs
Publication statusPublished - 1 Aug 2017
Externally publishedYes

Fingerprint

Dive into the research topics of 'Epigenetic modulation in cancer immunotherapy'. Together they form a unique fingerprint.

Cite this